Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
企業コードEVOK
会社名Evoke Pharma Inc
上場日Sep 25, 2013
最高経営責任者「CEO」Mr. Matthew J. (Matt) D'Onofrio
従業員数3
証券種類Ordinary Share
決算期末Sep 25
本社所在地420 Stevens Avenue
都市SOLANA BEACH
証券取引所London Stock Exchange
国United States of America
郵便番号92075
電話番号18583451494
ウェブサイトhttps://evokepharma.com/
企業コードEVOK
上場日Sep 25, 2013
最高経営責任者「CEO」Mr. Matthew J. (Matt) D'Onofrio
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし